➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Merck
Baxter
Johnson and Johnson
Dow

Last Updated: October 22, 2020

DrugPatentWatch Database Preview

Details for Patent: 6,239,180

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,239,180 protect, and when does it expire?

Patent 6,239,180 protects QUTENZA and is included in one NDA.

This patent has sixteen patent family members in ten countries.

Summary for Patent: 6,239,180
Title: Transdermal therapeutic device and method with capsaicin and capsaicin analogs
Abstract:Transdermal application of capsaicin (or a capsaicin analog) in a concentration from greater than about 5% to about 10% by weight has been discovered to be an extremely effective therapy for treating neuropathic pain, so long as an anesthetic, preferably by means of a transdermal patch, is administered initially to the affected area to minimize the expected side effects from subsequent capsaicin application.
Inventor(s): Robbins; Wendye R. (San Mateo, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Application Number:08/990,633
Patent Claim Types:
see list of patent claims
Use; Device; Formulation; Delivery;

Drugs Protected by US Patent 6,239,180

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Averitas QUTENZA capsaicin PATCH;TOPICAL 022395-001 Nov 16, 2009 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,239,180

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 240723   Start Trial
Austria 344023   Start Trial
Canada 2314326   Start Trial
Cyprus 1107582   Start Trial
Germany 69814917   Start Trial
Germany 69836352   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Medtronic
Harvard Business School
Moodys
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.